Advertisement
Australia markets open in 52 minutes
  • ALL ORDS

    7,975.10
    -64.80 (-0.81%)
     
  • AUD/USD

    0.6652
    -0.0006 (-0.09%)
     
  • ASX 200

    7,733.70
    -62.30 (-0.80%)
     
  • OIL

    81.68
    +0.05 (+0.06%)
     
  • GOLD

    2,344.60
    +0.20 (+0.01%)
     
  • Bitcoin AUD

    90,189.08
    -5,457.88 (-5.71%)
     
  • CMC Crypto 200

    1,249.68
    -60.04 (-4.58%)
     

One Genetic Technologies Insider Raised Stake By 20% In Previous Year

Looking at Genetic Technologies Limited's (ASX:GTG ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

View our latest analysis for Genetic Technologies

Genetic Technologies Insider Transactions Over The Last Year

In fact, the recent purchase by Peter Rubinstein was the biggest purchase of Genetic Technologies shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at around the current price of AU$0.14. That means they have been optimistic about the company in the past, though they may have changed their mind. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. In this case we're pleased to report that the insider bought shares at close to current prices. The only individual insider to buy over the last year was Peter Rubinstein.

ADVERTISEMENT

The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

Genetic Technologies is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does Genetic Technologies Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data indicates that Genetic Technologies insiders own about AU$1.4m worth of shares (which is 8.7% of the company). Whilst better than nothing, we're not overly impressed by these holdings.

So What Do The Genetic Technologies Insider Transactions Indicate?

It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Genetic Technologies stock. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 4 warning signs for Genetic Technologies you should be aware of, and 1 of these is a bit concerning.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.